Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck
cancer discontinued

EQS-Ad-hoc: Merck KGaA / Key word(s): Study results
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck
cancer discontinued

24-Jun-2024 / 19:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Disclosure of inside information pursuant to Article 17 of Regulation (EU)
No 596/2014

Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck
cancer discontinued

Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of
xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus
CRT, in patients with unresected locally advanced head and neck cancer in a
phase III clinical trial (TrilynX). The company decided to discontinue this
study. The decision follows a pre-planned interim analysis performed by the
study's Independent Data Monitoring Committee, which found that the trial
would be unlikely to meet its primary objective of prolonging event-free
survival. Given the totality of the data, the company decided to also stop
the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy,
compared to placebo plus radiotherapy in patients who underwent resection of
locally advanced head and neck cancer).

Xevinapant is currently under clinical investigation and not approved for
any indication anywhere in the world.

Esther Döringer
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151 1454 7809
Email: esther.doeringer@merckgroup.com
Internet: https://www.merckgroup.com/en
ISIN: DE0006599905
WKN: 659990
Indices: DAX

Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard);
Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart;
EUREX derivatives exchange; London, SIX




Contact:
Esther Döringer, Head of Media Relations


End of Inside Information

---------------------------------------------------------------------------

24-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Merck KGaA
                   Frankfurter Str. 250
                   64293 Darmstadt
                   Germany
   Phone:          +49 (0)6151 72 - 2702
   E-mail:         Friederike.Segeberg@merckgroup.com
   Internet:       https://www.merckgroup.com/de
   ISIN:           DE0006599905
   WKN:            659990
   Indices:        DAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate
                   Exchange; London, SIX
   EQS News ID:    1931843

End of Announcement EQS News Service
---------------------------------------------------------------------------

1931843 24-Jun-2024 CET/CEST